Articles by Rita Peters - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Rita Peters

Rita Peters

Editorial Director

Articles
Contract Providers Assume Expanded Responsibilities
September 1, 2014

Contract service providers are playing a more diverse role in drug development.

Meeting the Challenges of Excipient Variability
September 1, 2014

The quality and composition of excipients can vary due to environmental factors, processing methods, raw material quality, manufacturing location changes, and even operator actions.

API Developers Pass Inspections and Upgrade Capabilities
September 1, 2014

API development and manufacturing companies expanded their capabilities, built partnerships, and achieved milestones in regulatory inspections.

A Silver Milestone for Drug Development
August 2, 2014

Pharmaceutical Technology Europe marks 25 years of drug-development advances.

Shifting Gears in Drug Development Outsourcing Responsibilities
August 1, 2014

For a bio/pharma industry in flux, contract services are playing a greater—and more diverse—role in drug development.

Benefits and Risks of Drug Information on Social Media
July 2, 2014

FDA draft guidances seek to maintain accurate drug information for patients in new media.

US Biopharma Worries About Losing Lead in Innovation
May 2, 2014

Changes are needed to maintain US biopharma innovation leadership.

Biopharma Takes a Nervous Glance Over Its Shoulder
May 2, 2014

Changes are needed to maintain US biopharma innovation leadership.

Publishing Beyond the Printed Page
April 2, 2014

More media options open publishing opportunities for drug development experts.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
FindPharma Custom Search
Click here